A persistent gap exists where academic innovators develop brilliant science but fail to articulate how it becomes a product. Investors can't fund technology 'thrown over the transom'; they need to see a clear Target Product Profile (TPP) and a path to a return on investment, even at the earliest stages.
To improve efficiency and ethics in preclinical trials, Charles River is using aggregated natural history data to create synthetic control arms. This 'animal digital twin' approach significantly reduces the number of live animals required for placebo dosing, a simple yet transformative idea for drug development.
The primary bottleneck in U.S. clinical trials is not the FDA's 30-day IND approval process, but the slow, expensive 'nuts and bolts' of site activation. This includes redundant budget negotiations, contract formats, and separate scientific and IRB reviews for the same protocol across multiple institutions.
A key solution to clinical trial delays is for elite NCI-designated cancer centers to accept each other's IRB approvals. If a protocol is approved by MD Anderson, for example, Fred Hutch should honor it without a redundant review. This would eliminate months from the study startup phase.
Contrary to the 'garbage in, garbage out' rule, advanced AI is becoming so adept at pattern recognition that it can identify and isolate anomalies and errors within large, imperfect datasets. This capability reduces the burden of perfect data curation, suggesting AI can 'grow up' and clean its own inputs.
The integration of AI in drug development has been extraordinarily fast. What were vague, 'hand wavy' AI/ML claims on pitch decks just 3-4 years ago have, since ChatGPT's 2022 arrival, become a fundamental, end-to-end retooling of how the industry discovers and develops drugs.